Metabolites Profiling of Melanoma Interstitial Fluids Reveals Uridine Diphosphate as Potent Immune Modulator Capable of Limiting Tumor Growth

Tumor interstitial fluid (TIF) surrounds and perfuses tumors and collects ions, metabolites, proteins, and extracellular vesicles secreted by tumor and stromal cells. Specific metabolites, accumulated within the TIF, could induce metabolic alterations of immune cells and shape the tumor microenvironment. We deployed a metabolomic approach to analyze the composition of melanoma TIF and compared it to the plasma of C57BL6 mice, engrafted or not with B16-melanoma cells. Among the classes of metabolites analyzed, monophosphate and diphosphate nucleotides resulted enriched in TIF compared to plasma samples. The analysis of the effects exerted by guanosine diphosphate (GDP) and uridine diphosphate (UDP) on immune response revealed that GDP and UDP increased the percentage of CD4+CD25+FoxP3– and, on isolated CD4+ T-cells, induced the phosphorylation of ERK, STAT1, and STAT3; increased the activity of NF-κB subunits p65, p50, RelB, and p52; increased the expression of Th1/Th17 markers including IFNγ, IL17, T-bet, and RORγt; and reduced the expression of IL13, a Th2 marker. Finally, we observed that local administrations of UDP in B16-engrafted C57BL6 mice reduced tumor growth and necrotic areas. In addition, UDP-treated tumors showed a higher presence of MHCIIhi tumor-associated macrophage (TAM) and of CD3+CD8+ and CD3+CD4+ tumor-infiltrating T-lymphocytes (TILs), both markers of anti-tumor immune response. Consistent with this, intra-tumoral gene expression analysis revealed in UDP-treated tumors an increase in the expression of genes functionally linked to anti-tumor immune response. Our analysis revealed an important metabolite acting as mediator of immune response, which could potentially represent an additional tool to be used as an adjuvant in cancer immunotherapy.

Abstract licence: CC BY

1. 14.

   Transition of tumor-associated macrophages from MHC class IIhi to MHC class IIlow mediates tumor progression in mice · 2011

2. 29.

   Inhibition of UDP/P2Y 6 purinergic signaling prevents phagocytosis of viable neurons by activated microglia in vitro and in vivo · 2014

3. 47.

   Defining Memory CD8 T Cell · 2018

4. 51.

   Targeting immune cells for cancer therapy · 2019

5. 55.

   Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability · 2019

6. 63.

   Targeting tumor-associated macrophages to synergize tumor immunotherapy · 2021

7. 64.

   The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy · 2021

61 more references, whose wording the paper’s licence keeps private.

• Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy · 2022

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.